Lindbrook Capital LLC Has $220,000 Stock Position in Agilent Technologies, Inc. (NYSE:A)

Lindbrook Capital LLC boosted its stake in shares of Agilent Technologies, Inc. (NYSE:A) by 54.0% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,580 shares of the medical research company’s stock after buying an additional 554 shares during the period. Lindbrook Capital LLC’s holdings in Agilent Technologies were worth $220,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. OFI Invest Asset Management purchased a new stake in shares of Agilent Technologies in the third quarter valued at $25,000. MV Capital Management Inc. boosted its position in Agilent Technologies by 120.7% during the 4th quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after acquiring an additional 105 shares during the period. Baystate Wealth Management LLC grew its stake in Agilent Technologies by 107.3% during the 4th quarter. Baystate Wealth Management LLC now owns 257 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 133 shares in the last quarter. Column Capital Advisors LLC increased its holdings in shares of Agilent Technologies by 1,111.1% in the 3rd quarter. Column Capital Advisors LLC now owns 327 shares of the medical research company’s stock valued at $37,000 after purchasing an additional 300 shares during the period. Finally, Rosenberg Matthew Hamilton lifted its position in shares of Agilent Technologies by 51.1% in the fourth quarter. Rosenberg Matthew Hamilton now owns 284 shares of the medical research company’s stock worth $39,000 after purchasing an additional 96 shares in the last quarter.

Agilent Technologies Stock Up 0.9 %

A opened at $133.91 on Tuesday. The business has a 50 day moving average of $141.21 and a 200-day moving average of $130.08. The stock has a market capitalization of $39.24 billion, a price-to-earnings ratio of 31.88, a P/E/G ratio of 4.02 and a beta of 1.11. The company has a current ratio of 2.68, a quick ratio of 2.04 and a debt-to-equity ratio of 0.41. Agilent Technologies, Inc. has a 1-year low of $96.80 and a 1-year high of $151.58.

Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.07. The company had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. Agilent Technologies had a net margin of 18.35% and a return on equity of 27.09%. The business’s quarterly revenue was down 5.5% on a year-over-year basis. During the same period last year, the business posted $1.37 EPS. As a group, sell-side analysts anticipate that Agilent Technologies, Inc. will post 5.51 earnings per share for the current year.

Agilent Technologies Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 24th. Stockholders of record on Tuesday, April 2nd will be issued a dividend of $0.236 per share. This represents a $0.94 annualized dividend and a dividend yield of 0.70%. The ex-dividend date of this dividend is Monday, April 1st. Agilent Technologies’s payout ratio is presently 22.38%.

Analysts Set New Price Targets

A has been the topic of several research reports. Evercore ISI upped their price objective on shares of Agilent Technologies from $132.00 to $145.00 and gave the company an “in-line” rating in a research note on Thursday, April 4th. UBS Group upped their price target on shares of Agilent Technologies from $130.00 to $155.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 28th. Stifel Nicolaus raised Agilent Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $145.00 to $163.00 in a research report on Friday, April 5th. Barclays upped their target price on Agilent Technologies from $125.00 to $135.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Finally, Citigroup lifted their price target on Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $141.29.

Insider Activity at Agilent Technologies

In other news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total transaction of $239,315.72. Following the sale, the director now directly owns 54,976 shares in the company, valued at approximately $7,935,235.84. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Heidi Fields sold 1,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $144.34, for a total transaction of $239,315.72. Following the completion of the transaction, the director now owns 54,976 shares in the company, valued at approximately $7,935,235.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Philip Binns sold 2,827 shares of the company’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the sale, the senior vice president now owns 9,997 shares in the company, valued at $1,474,957.38. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 61,610 shares of company stock worth $9,220,333.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.